Skip to main content
Fig. 5 | Orphanet Journal of Rare Diseases

Fig. 5

From: Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial

Fig. 5

Percent predicted diffusing  capacity of the lung for carbon monoxide (DLCO) adjusted for hemoglobin and barometric pressure during placebo or olipudase alfa treatment periods. Means are shown above and below the lines for the group crossing over to olipudase alfa from placebo and the olipudase alfa group, respectively. Percent predicted DLCO values > 80% were considered normal without impairment, > 60–80% mild impairment, 40–60% moderate impairment, and < 40% severe impairment [29, 30]

Back to article page